Editas Medicine Q3 2023 net loss $45.0M; cash $446.4M; EDIT-301 data at ASH

Editas Medicine, Inc.

2023-Q3 EPS reported -$1.81 revenue$18,074,000

Net loss of $45.0M ($0.55/share) vs $55.7M ($0.81/share) in Q3 2022.
Collaboration revenue $5.3M vs $42K, driven by Vor Bio Cas9 license upfront payment.
Cash and securities $446.4M; expected to fund operations into Q3 2025.
EDIT-301 clinical update from RUBY (SCD) and EdiTHAL (TDT) at ASH Dec 11.
Appointed Caren Deardorf as first Chief Commercial and Strategy Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Editas Medicine, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $5.3 million, net income $45.0 million net loss, EPS $0.55 per share.

Period: the fiscal quarter ended September 30, 2023
Revenue: $5.3 million
Net income: $45.0 million net loss
EPS: $0.55 per share
Result: reported results

Exact text from the filing

$0.55 per share, compared to net loss of $55.7 million, or $0.81 per share, for the same period in 2022. • Collaboration and other research and development revenues increased to $5.3 million for the three months ended September 30, 2023, compared to $42.0 thousand for the same period in 2022. The increase is primarily related to an upfront payment for the

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.